Pitolisant (BF2.649)

DRUG3 trials

Sponsors

Bioprojet

Conditions

Alcohol Abuse, Nervous SystemExcessive Daytime SleepinessObstructive Sleep Apnea

Phase 2

A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment

WithdrawnNCT02800083

BioprojetAlcohol Abuse, Nervous System

Start: 2016-10-31Updated: 2017-01-12

Phase 3

Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA

CompletedNCT02739568

BioprojetExcessive Daytime Sleepiness, Obstructive Sleep Apnea

Start: 2016-04-30End: 2020-04-30Updated: 2020-07-08

Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness

WithdrawnNCT02978651

BioprojetExcessive Daytime Sleepiness, Obstructive Sleep Apnea

Updated: 2017-11-24